It has been further hypothesized that inhibition of DDR1 may be a way to downregulate the tumor-inducing actions of the insulin/IGF system in human cancer cells while simultaneously inducing differentiation of cells without affecting the IR-B mediated metabolic actions [60]. The gene discussed is INS; the disease is cancer.